Kalorama Information studies on the pharmaceutical vaccines industry cover the global market opportunity in full, with data on major competitors, market direction, and the pediatric and adult segments. Kalorama reports examine the global vaccines market by region, including the US, South America, EU, Japan, India, and China, as well as by type, including hepatitis, pneumococcal, cervical cancer, and influenza, among others. Market share of major vaccine companies is reported as well.
- Sort by Product ID
- Display 30 Products per page
Published: February 22, 2024 | Price: $5,000.00 – $10,500.00
Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century. Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated...Published: September 23, 2022 | Price: $5,000.00 – $10,000.00
V A C C I N E M A R K E T E X C E E D S $200 B I L L I O N In 2022, the global market for preventive vaccines is valued at $202.6 billion. That's up from $34.1 billion in 2017, and just $25 billion in 2010. Infectious diseases are some of the deadliest diseases that pose significant risk to human life. Sales increased from $127.6 billion in 2021 to $202.6 billion in...Published: November 4, 2020 | Price: $4,000.00 – $8,000.00
Vaccine Market Tops 37 Billion, Says Kalorama Information Report In 2020, the global market for preventive vaccines is valued at $37.4 billion, up overall from $30.7 billion in 2015. The finding was made in Kalorama Information's report, Vaccines 2020. Strong continued growth in the global vaccines market is expected through 2025. THE MOST CURRENT VACCINE MARKET INFORMATION The vaccine market is a growth market for the experienced competitors participating in it.Seven billion dollars in new sales have occurred in the past...Published: April 21, 2020 | Price: $4,000.00 – $8,000.00
The vaccine market is poised for a rather substantial increase in the next five years due to the number of vaccines in development and the push for a COVID-19 vaccine. As the COVID-19 outbreak advanced worldwide, companies stepped up to the challenge, scrambling to provide a potential vaccine. In addition to discussion of COVID-19 vaccine development as it stands currently, this report examines the market for human vaccines used to prevent various types of disease, focusing on commercialized vaccines and...Published: August 8, 2018 | Price: $4,500.00 – $9,000.00
Vaccines 2018-2024: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others) Vaccines 2018: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments provides a complete global revenue summary, including the total global market for preventive vaccines by type for 2015 to 2024 (pediatric total: combinations, hepatitis, haemophilus influenzae type B, measles, mumps and rubella, pneumococcal, poliovirus, varicella, others; adult total: cervical, hepatitis, influenza, pneumococcal, travel and other;...Published: March 25, 2016 | Price: $3,360.00 – $6,720.00
Vaccines 2016: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others) Vaccines: The World Market analyzes the revenues for vaccines used in humans to prevent various types of disease. The report provides a comprehensive revenue summary, including revenue growth of vaccines vs. pharmaceuticals, 2013-2022; global market for vaccines by type, pediatric vs. adult, 2013-2022; global vaccines revenues by vaccine type, 2013-2022 (pediatric: combinations, hepatitis, HIB, MMR, pneumococcal,...Published: November 12, 2015 | Price: $2,100.00 – $4,200.00
This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types) including Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy. The report has a special emphasis on novel treatments and provides an overview of...Published: August 29, 2014 | Price: $3,995.00 – $7,990.00
Biopharmaceutical and Vaccine Production Markets Biopharmaceutical and Vaccine Production Markets analyzes the entire manufacturing market for biologic drugs, including both outsourcing and costs by major maufacturers spending internally on biopharmaceutical and vaccine production. As part of its coverage, the following information is provided Market Size and Projections Vaccine Manufacturing Estimates Biologic Drug Methods Trend Analysis Types of Production Outsourcing Market Regulation of the Market Competitor Profiles This study contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other...Published: April 21, 2014 | Price: $995.00 – $1,990.00
Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission....Published: December 4, 2012 | Price: $500.00 – $1,000.00
This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including: Breast Colorectal Head/Neck Kidney Leukemia Liver Lung Melanoma Ovarian Pancreatic Prostate Stomach The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar...Published: October 18, 2012 | Price: $3,995.00 – $7,990.00
Vaccines are an important part of the business model of top pharmaceutical companies. The success of several recent vaccine product introductions has been of great interest to pharma R&D efforts. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth in many categories through 2011, declines in others, and this is expected to continue through the forecast period. Growth is being fueled...Published: September 19, 2012 | Price: $1,500.00 – $3,000.00
This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) infection, etc.; vaccines that address these and other not-yet-vaccine-preventable conditions are...Published: June 5, 2012 | Price: $3,995.00 – $7,990.00
Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines in the pipeline.This Kalorama Information report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched. What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can...Published: February 1, 2012 | Price: $2,500.00 – $5,000.00
Vaccines are among the top revenue earners in recent years, and in some cases have assisted major pharmaceutical companies to revenue growth. But this is not without some trade-offs. Vaccines involve a complex production process. Is vaccine-making profitable? How much is the industry spending? How much is handed off to other companies and how much is made by the branded manufacturers? How many doses are produced by the industry? These are the type of questions that Kalorama Information has taken...Published: July 1, 2011 | Price: $150.00 – $300.00
As researchers work to improve drug properties through drug design and molecular modeling, the line between drug delivery and drug substance will become more and more elusive in the near future, as shown in the analysis in this report. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry and the needle-free drug delivery market will continue to grow rapidly. This Kalorama Information report, Needle-Free Drug Delivery: The Market for Alternatives...Published: July 1, 2011 | Price: $150.00 – $225.00
The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth through 2010 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions. Kalorama Information has been closely following vaccine markets and has instituted a yearly market research report schedule since 2003 in order to keep up with fast-moving...Published: March 25, 2011 | Price: $150.00 – $300.00
The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from these emerging vaccine markets. The population of nearly 4 billion people throughout Asia accounts for more than half of the global population, yet currently it is Western markets which lead vaccine sales. This hasn't stopped companies from investing in Asian vaccine markets. The graying of the population in Asia and the growth in some regions...Published: November 1, 2010 | Price: $995.00 – $3,000.00
The European vaccines market has demonstrated growth even through tough economic times. This has mainly been due to the introduction of vaccines in untapped disease markets and government’s acceptance and willingness to pay for new products. This has encouraged market participants to increase spending in research and development. This report, European Vaccine Markets, examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable;...Published: September 1, 2010 | Price: $1,500.00 – $3,000.00
Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even with achievements for some companies, numerous vaccines with apparently strong...Published: August 1, 2010 | Price: $3,995.00 – $7,990.00
Vaccines have been one of the faster growing areas of the pharmaceutical industry, and during a troubling series of years, they have been the superstars of many companies' portfolios. They've also attracted the attention of insurance companies, retail outlets and the media. The global market for vaccines experienced strong growth through 2009 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions. Kalorama Information has been...Published: May 1, 2010 | Price: $500.00 – $2,400.00
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and...Published: February 1, 2010 | Price: $1,500.00 – $8,400.00
The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine...Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...Published: June 1, 2009 | Price: $3,995.00 – $7,990.00
The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions. This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are...Published: November 1, 2008 | Price: $3,995.00 – $7,990.00
It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products. There are several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming...Published: April 1, 2008 | Price: $995.00 – $8,200.00
Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first...Published: February 1, 2007 | Price: $3,995.00 – $7,990.00
What are the trends that are fueling a new boom in vaccine production and sales? Why is an industry so commonly associated with children finding an increasing marketplace among adult populations? What makes this class of drugs likely to grow at a faster rate than other pharmaceutical products? These are among the questions answered in Kalorama’s in-depth report, Vaccines: The World Market. With the historic success of vaccines in virtually eliminating diseases such as small pox and polio, and with...Published: November 1, 2006 | Price: $1,200.00 – $7,000.00
Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Prostate cancer, and Other cancers for which vaccines are in development. Each market segment provides an overview, descriptions of products available...Published: November 1, 2004 | Price: $3,500.00 – $7,000.00
This report covers pediatric and adult preventive vaccine products and provides an analysis of therapeutic vaccines for cancer treatment. In assessing the market for vaccine products, Kalorama Information provides sales data for the 2001-2003 historical years, the 2004 base year, and the 2001 through 2010 forecast years. Revenues are expressed in terms of manufacturers’ annual sales and in current U.S. dollars. The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources...Published: January 1, 2004 | Price: $3,500.00 – $7,000.00
The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...